Promising effect of Magliasa, a traditional Iranian formula, on experimental colitis on the basis of biochemical and cellular findings

World Journal of Gastroenterology

Volumn 19, Issue 12, 2013, Pages 1901-1911

  Rahimi, Roja ^a   Baghaei, Amir ^a   Baeeri, Maryam ^a   Amin, Gholamreza ^a   Shams Ardekani, Mohammad Reza ^a   Khanavi, Mahnaz ^a   Abdollahi, Mohammad ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Colitis; Inflammatory cytokines; Magliasa; Neutrophil infiltration; Oxidative stress; Traditional Iranian medicine

Indexed keywords

GLUCOSINOLATE; INTERLEUKIN 1BETA; MAGLIASA; MYELOPEROXIDASE; PHENOL; PLANT EXTRACT; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; HYPEREMIA; INFLAMMATION; LD 50; LIPID PEROXIDATION; MALE; NONHUMAN; QUANTITATIVE ANALYSIS; RAT; SCORING SYSTEM; SPECTROPHOTOMETRY; THIN LAYER CHROMATOGRAPHY;

EID: 84875576691     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i12.1901     Document Type: Article

References (93)

1. Brown SJ, Mayer L. The immune response in inflammatory bowel disease. Am J Gastroenterol 2007; 102: 2058-2069 [PMID: 17561966 DOI: 10.1111/j.1572-0241.2007.01343.x]
2. Rezaie A, Parker RD, Abdollahi M. Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause? Dig Dis Sci 2007; 52: 2015-2021 [PMID: 17404859 DOI: 10.1007/s10620-006-9622-2]
3. Reiff C, Kelly D. Inflammatory bowel disease, gut bacteria and probiotic therapy. Int J Med Microbiol 2010; 300: 25-33 [PMID: 19800289 DOI: 10.1016/j.ijmm.2009.08.004]
4. Kucharzik T, Maaser C, Lügering A, Kagnoff M, Mayer L, Targan S, Domschke W. Recent understanding of IBD pathogenesis: implications for future therapies. Inflamm Bowel Dis 2006; 12: 1068-1083 [PMID: 17075348]
5. Martín MC, Martinez A, Mendoza JL, Taxonera C, Díaz-Rubio M, Fernández-Arquero M, de la Concha EG, Urcelay E. Influence of the inducible nitric oxide synthase gene (NOS2A) on inflammatory bowel disease susceptibility. Immunogenetics 2007; 59: 833-837 [PMID: 17955236 DOI: 10.1007/ s00251-007-0255-1]
6. Rezaie A, Khalaj S, Shabihkhani M, Nikfar S, Zamani MJ, Mohammadirad A, Daryani NE, Abdollahi M. Study on the correlations among disease activity index and salivary transforming growth factor-beta 1 and nitric oxide in ulcerative colitis patients. Ann N Y Acad Sci 2007; 1095: 305-314 [PMID: 17404043]
7. Rezaie A, Ghorbani F, Eshghtork A, Zamani MJ, Dehghan G, Taghavi B, Nikfar S, Mohammadirad A, Daryani NE, Abdollahi M. Alterations in salivary antioxidants, nitric oxide, and transforming growth factor-beta 1 in relation to disease activity in Crohn's disease patients. Ann N Y Acad Sci 2006; 1091: 110-122 [PMID: 17341608]
8. Jahanshahi G, Motavasel V, Rezaie A, Hashtroudi AA, Daryani NE, Abdollahi M. Alterations in antioxidant power and levels of epidermal growth factor and nitric oxide in saliva of patients with inflammatory bowel diseases. Dig Dis Sci 2004; 49: 1752-1757 [PMID: 15628697 DOI: 10.1007/ s10620-004-9564-5]
9. El Miedany Y, Youssef S, Ahmed I, El Gaafary M. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. Am J Gastroenterol 2006; 101: 311-317 [PMID: 16454836 DOI: 10.1111/j.1572-0241.2006.00384.x]
10. Rahimi R, Nikfar S, Abdollahi M. Meta-analysis technique confirms the effectiveness of anti-TNF-alpha in the management of active ulcerative colitis when administered in combination with corticosteroids. Med Sci Monit 2007; 13: PI13-PI18 [PMID: 17599035]
11. Rahimi R, Nikfar S, Abdollahi M. Do anti-tumor necrosis factors induce response and remission in patients with acute refractory Crohn's disease? A systematic meta-analysis of controlled clinical trials. Biomed Pharmacother 2007; 61: 75-80 [PMID: 17184965 DOI: 10.1016/j.biopha.2006.06.022]
12. Nikfar S, Ehteshami-Afshar S, Abdollahi M. A systematic review and meta-analysis of the efficacy and adverse events of infliximab in comparison to corticosteroids and placebo in active ulcerative colitis. Int J Pharmacol 2011; 7: 325-332 [DOI: 10.3923/ijp.2011.325.332]
13. Khan KJ, Dubinsky MC, Ford AC, Ullman TA, Talley NJ, Moayyedi P. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 630-642 [PMID: 21407186 DOI: 10.1038/ajg.2011.64]
14. Nikfar S, Mirfazaelian H, Abdollahi M. Efficacy and tolerability of immunoregulators and antibiotics in fistulizing Crohn's disease: a systematic review and meta-analysis of placebo-controlled trials. Curr Pharm Des 2010; 16: 3684-3698 [PMID: 21143147 DOI: 10.2174/13816121079407923]
15. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. A meta-analysis of antibiotic therapy for active ulcerative colitis. Dig Dis Sci 2007; 52: 2920-2925 [PMID: 17415632 DOI: 10.1007/ s10620-007-9760-1]
16. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. A meta-analysis of broad-spectrum antibiotic therapy in patients with active Crohn's disease. Clin Ther 2006; 28: 1983-1988 [PMID: 17296455 DOI: 10.1016/j.clinthera.2006.12.012]
17. Rahimi R, Nikfar S, Abdollahi M. A meta-analysis of the benefit of probiotics in maintaining remission of human ulcerative colitis: evidence for prevention of disease relapse and maintenance of remission. Arch Med Sci 2008; 4: 185-190
18. Rahimi R, Nikfar S, Rahimi F, Elahi B, Derakhshani S, Vafaie M, Abdollahi M. A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease. Dig Dis Sci 2008; 53: 2524-2531 [PMID: 18270836 DOI: 10.1007/s10620-007-0171-0]
19. Triantafillidis JK, Merikas E, Georgopoulos F. Current and emerging drugs for the treatment of inflammatory bowel disease. Drug Des Devel Ther 2011; 5: 185-210 [PMID: 21552489]
20. Nikfar S, Rahimi R, Rezaie A, Abdollahi M. A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis. Dig Dis Sci 2009; 54: 1157-1170 [PMID: 18770034 DOI: 10.1007/s10620-008-0481-x]
21. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Comparison of mesalazine and balsalazide in induction and maintenance of remission in patients with ulcerative colitis: a meta-analysis. Dig Dis Sci 2009; 54: 712-721 [PMID: 18683049 DOI: 10.1007/ s10620-008-0428-2]
22. Nikfar S, Ehteshami-Ashar S, Rahimi R, Abdollahi M. Systematic review and meta-analysis of the efficacy and tolerability of nicotine preparations in active ulcerative colitis. Clin Ther 2010; 32: 2304-2315 [PMID: 21353102 DOI: 10.1016/ j.clinthera.2011.01.004]
23. Hosseini-Tabatabaei A, Abdollahi M. Potassium channel openers and improvement of toxic stress: do they have role in the management of inflammatory bowel disease? Inflamm Allergy Drug Targets 2008; 7: 129-135 [PMID: 18782019 DOI: 10.2174/187152808785748164]
24. Salari P, Abdollahi M. Current opinion in the pharmaceutical management of irritable and inflammatory bowel diseases: Role of ATP. Recent Pat Endocr Metab Immune Drug Discov 2009; 3: 69-75 [DOI: 10.2174/187221409787002949]
25. Khoshakhlagh P, Bahrololoumi-Shapourabadi M, Mohammadirad A, Ashtaral-Nakhai L, Minaie B, Abdollahi M. Beneficial effect of phosphodiesterase-5 inhibitor in experimental inflammatory bowel disease; molecular evidence for involvement of oxidative stress. Toxicol Mech Methods 2007; 17: 281-288 [PMID: 20020951 DOI: 10.1080/15376510601003769]
26. Salari-Sharif P, Abdollahi M. Phosphodiesterase 4 inhibitors in inflammatory bowel disease: a comprehensive review. Curr Pharm Des 2010; 16: 3661-3667 [PMID: 21128899]
27. Rahimi R, Ghiasi S, Azimi H, Fakhari S, Abdollahi M. A review of the herbal phosphodiesterase inhibitors; future perspective of new drugs. Cytokine 2010; 49: 123-129 [PMID: 20005737]
28. Stein RB, Hanauer SB. Comparative tolerability of treatments for inflammatory bowel disease. Drug Saf 2000; 23: 429-448 [PMID: 11085348 DOI: 10.2165/00002018-200023050-00006]
29. Stallmach A, Hagel S, Bruns T. Adverse effects of biologics used for treating IBD. Best Pract Res Clin Gastroenterol 2010; 24: 167-182 [PMID: 20227030 DOI: 10.1016/j.bpg.2010.01.002]
30. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis. Reprod Toxicol 2008; 25: 271-275 [PMID: 18242053 DOI: 10.1016/ j.reprotox.2007.11.010]
31. Rahimi R, Mozaffari S, Abdollahi M. On the use of herbal medicines in management of inflammatory bowel diseases: a systematic review of animal and human studies. Dig Dis Sci 2009; 54: 471-480 [PMID: 18618255 DOI: 10.1007/s10620-008-0368-x]
32. Rahimi R, Shams-Ardekani MR, Abdollahi M. A review of the efficacy of traditional Iranian medicine for inflammatory bowel disease. World J Gastroenterol 2010; 16: 4504-4514 [PMID: 20857519 DOI: 10.3748/wjg.v16.i36.4504]
33. Ardekani MR, Rahimi R, Javadi B, Abdi L, Khanavi M. Relationship between temperaments of medicinal plants and their major chemical compounds. J Tradit Chin Med 2011; 31: 27-31 [PMID: 21563502 DOI: 10.1016/S0254-6272(11)60006-X]
34. Arzani MA. Tebb-e-akbari [in Persian]. Institute of Revival of Natural Medicine, 2007: 778-781
35. Tonkaboni MM. Tohfeh al-Momenin [in Persian]. Shahid Beheshti University of Medical Sciences, 2007: 356-542
36. Aghili MH. Makhzan-al-Advia [in Persian]. Tehran University of Medical Sciences, 2009: 165-742
37. Amin G. Popular medicinal plants of Iran. Tehran University of Medical Sciences, 2008: 104-264
38. World Health Organization. Quality control methods for medicinal plant materials. Geneva: World Health Organization, 1998: 5
39. Smith CA, Dacombe C. Rapid method for determining total glucosinolates in rapeseed by measurement of enzymatically released glucose. J Sci Food Agric 1987; 38: 141-150 [DOI: 10.1002/jsfa.2740380206]
40. Singleton VL, Orthofer R, Lamuela-Raventos RM. Analysis of total phenols and other oxidation substrates and antioxidants by means of Folin-Ciocalteu reagent. Methods Enzymol 1999; 299: 152-178 [DOI: 10.1016/S0076-6879(99)99017-1]
41. Wagner H, Bladt S. Plant Drug Analysis: A Thin Layer Chromatography Atlas. 2nd ed. Springer, 2001: 149-152
42. Baghaei A, Esmaily H, Abdolghaffari AH, Baeeri M, Gharibdoost F, Abdollahi M. Efficacy of Setarud (IMod), a novel drug with potent anti-toxic stress potential in rat inflammatory bowel disease and comparison with dexamethasone and infliximab. Indian J Biochem Biophys 2010; 47: 219-226 [PMID: 21174949]
43. Abdolghaffari AH, Baghaei A, Moayer F, Esmaily H, Baeeri M, Monsef-Esfahani HR, Hajiaghaee R, Abdollahi M. On the benefit of Teucrium in murine colitis through improvement of toxic inflammatory mediators. Hum Exp Toxicol 2010; 29: 287-295 [PMID: 20144954 DOI: 10.1177/0960327110361754]
44. Ebrahimi F, Esmaily H, Baeeri M, Mohammadirad A, Fallah S, Abdollahi M. Molecular evidences on the benefit of N-acetylcysteine in experimental colitis. Cent Eur J Biol 2008; 3: 135-132 [DOI: 10.2478/s11535-008-0005-x]
45. Ghafari H, Yasa N, Mohammadirad A, Dehghan G, Zamani MJ, Nikfar S, Khorasani R, Minaie B, Abdollahi M. Protection by Ziziphora clinopoides of acetic acid-induced toxic bowel inflammation through reduction of cellular lipid peroxidation and myeloperoxidase activity. Hum Exp Toxicol 2006; 25: 325-332 [PMID: 16866190 DOI: 10.1191/0960327105ht626oa]
46. Nakhai LA, Mohammadirad A, Yasa N, Minaie B, Nikfar S, Ghazanfari G, Zamani MJ, Dehghan G, Jamshidi H, Boushehri VS, Khorasani R, Abdollahi M. Benefits of Zataria multiflora Boiss in Experimental Model of Mouse Inflammatory Bowel Disease. Evid Based Complement Alternat Med 2007; 4: 43-50 [PMID: 17342240 DOI: 10.1093/ecam/nel051]
47. Hasani P, Yasa N, Vosough-Ghanbari S, Mohammadirad A, Dehghan G, Abdollahi M. In vivo antioxidant potential of Teucrium polium, as compared to alpha-tocopherol. Acta Pharm 2007; 57: 123-129 [PMID: 19839412 DOI: 10.2478/ v10007-007-0010-z]
48. Ghazanfari G, Minaie B, Yasa N, Nakhai LA, Mohammadirad A, Nikfar S, Dehghan G, Boushehri VS, Jamshidi H, Khorasani R, Salehnia A, Abdollahi M. Biochemical and histopathological evidences for beneficial effects of satureja khuzestanica jamzad essential oil on the mouse model of inflammatory bowel diseases. Toxicol Mech Methods 2006; 16: 365-372 [PMID: 20021009]
49. Amini-Shirazi N, Hoseini A, Ranjbar A, Mohammadirad A, Khoshakhlagh P, Yasa N, Abdollahi M. Inhibition of tumor necrosis factor and nitrosative/oxidative stresses by Ziziphora clinopoides (Kahlioti); a molecular mechanism of protection against dextran sodium sulfate-induced colitis in mice. Toxicol Mech Methods 2009; 19: 183-189 [PMID: 19778264]
50. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254 [PMID: 942051]
51. Hodgson E. A textbook of modern toxicology. 3rd ed. New Jersey: John Wily and Sons, 2004 [DOI: 10.1002/0471646776]
52. Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011; 140: 1756-1767 [PMID: 21530742 DOI: 10.1053/ j.gastro.2011.02.016]
53. Cominelli F, Pizarro TT. Interleukin-1 and interleukin-1 receptor antagonist in inflammatory bowel disease. Aliment Pharmacol Ther 1996; 10 Suppl 2: 49-53; discussion 54 [PMID: 8899101]
54. Esmaily H, Vaziri-Bami A, Miroliaee AE, Baeeri M, Abdollahi M. The correlation between NF-κB inhibition and disease activity by coadministration of silibinin and ursodeoxycholic acid in experimental colitis. Fundam Clin Pharmacol 2011; 25: 723-733 [PMID: 21077947 DOI: 10.1111/ j.1472-8206.2010.00893.x]
55. Akazawa A, Sakaida I, Higaki S, Kubo Y, Uchida K, Okita K. Increased expression of tumor necrosis factor-alpha messenger RNA in the intestinal mucosa of inflammatory bowel disease, particularly in patients with disease in the inactive phase. J Gastroenterol 2002; 37: 345-353 [PMID: 12051533]
56. Komatsu M, Kobayashi D, Saito K, Furuya D, Yagihashi A, Araake H, Tsuji N, Sakamaki S, Niitsu Y, Watanabe N. Tumor necrosis factor-alpha in serum of patients with inflammatory bowel disease as measured by a highly sensitive immuno-PCR. Clin Chem 2001; 47: 1297-1301 [PMID: 11427462]
57. Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 644-659, quiz 660 [PMID: 21407183 DOI: 10.1038/ajg.2011.73]
58. Grulke S, Franck T, Gangl M, Péters F, Salciccia A, Deby-Dupont G, Serteyn D. Myeloperoxidase assay in plasma and peritoneal fluid of horses with gastrointestinal disease. Can J Vet Res 2008; 72: 37-42 [PMID: 18214160]
59. Miroliaee AE, Esmaily H, Vaziri-Bami A, Baeeri M, Shahverdi AR, Abdollahi M. Amelioration of experimental colitis by a novel nanoselenium-silymarin mixture. Toxicol Mech Methods 2011; 21: 200-208 [PMID: 21247366 DOI: 10.3109/153 76516.2010.547887]
60. Kassie F, Rabot S, Uhl M, Huber W, Qin HM, Helma C, Schulte-Hermann R, Knasmüller S. Chemoprotective effects of garden cress (Lepidium sativum) and its constituents towards 2-amino-3-methyl-imidazo[4,5-f]quinoline (IQ)-induced genotoxic effects and colonic preneoplastic lesions. Carcinogenesis 2002; 23: 1155-1161 [PMID: 12117773 DOI: 10.1093/carcin/23.7.1155]
61. Datta PK, Diwakar BT, Viswanatha S, Murthy KN, Naidu KA. Safety evaluation studies on Garden cress (Lepidium sativum L.) seeds in Wistar rats. Int J Appl Res Nat Prod 2011; 4: 37-43
62. Bafeel SO, Ali SS. The Potential Liver Toxicity of Lepidium sativum Seeds in Albino Rats. Res J Biol Sci 2009; 4: 1250-1258 [DOI: 10.3923/rjbsci.2009.1250.1258]
63. Moser BR, Shah SN, Moser JK, Vaughn SF, Evangelista RL. Composition and Physical Properties of Cress (Lepidium sativum L.) and Field Pennycress (Thlaspi arvense L.) Oils. Indust Crops Prod 2009; 30: 199-205 [DOI: 10.1016/ j.indcrop.2009.03.007]
64. Diwakar BT, Lokesh BR, Naidu KA. Modulatory effect of α-linolenic acid-rich garden cress (Lepidium sativum L.) seed oil on inflammatory mediators in adult albino rats. Br J Nutr 2011; 106: 530-539 [PMID: 21521541]
65. Al-Yahya MA, Mossa JS, Ageel AM, Rafatullah S. Pharmacological and safety evaluation studies on Lepidium sativum L., seeds. Phytomedicine 1994; 1: 155-159 [DOI: 10.1016/ S0944-7113(11)80035-8]
66. Najeeb-Ur-Rehman MH, Alkharfy KM, Gilani AH. Prokinetic and laxative activities of Lepidium sativum seed extract with species and tissue selective gut stimulatory actions. J Ethnopharmacol 2011; 134: 878-883 [PMID: 21296647 DOI: 10.1016/j.jep.2011.01.047]
67. Rehman NU, Mehmood MH, Alkharfy KM, Gilani AH. Studies on antidiarrheal and antispasmodic activities of Lepidium sativum crude extract in rats. Phytother Res 2012; 26: 136-141 [PMID: 22006354 DOI: 10.1002/ptr.3642]
68. Rehman NU, Khan AU, Alkharfy KM, Gilani AH. Pharmacological Basis for the Medicinal Use of Lepidium sativum in Airways Disorders. Evid Based Complement Alternat Med 2012; 2012: 596524 [PMID: 22291849 DOI: 10.1155/2012/596524]
69. Azizi M, Davareenejad G. Essential Oil Content and Constituents of Black Zira (Bunium persicum [Boiss.] B. Fedtsch.) from Iran During Field Cultivation (Domestication). J Essent Oil Res 2009; 21: 78-82 [DOI: 10.1080/10412905.2009.9700117]
70. Sharififar F, Yassa N, Mozaffarian V. Bioactivity of major components from the seeds of Bunium persicum (Boiss.) Fedtch. Pak J Pharm Sci 2010; 23: 300-304 [PMID: 20566444]
71. Nickavar B, Abolhasani FA. Screening of antioxidant properties of seven Umbelliferae fruits from Iran. Pak J Pharm Sci 2009; 22: 30-35 [PMID: 19168417]
72. Shahsavari N, Barzegar M, Sahari MA, Naghdibadi H. Antioxidant activity and chemical characterization of essential oil of Bunium persicum. Plant Foods Hum Nutr 2008; 63: 183-188 [PMID: 18810640]
73. Hajhashemi V, Sajjadi SE, Zomorodkia M. Antinociceptive and anti-inflammatory activities of Bunium persicum essential oil, hydroalcoholic and polyphenolic extracts in animal models. Pharm Biol 2011; 49: 146-151 [PMID: 20942602]
74. Singh KK, Mridula D, Rehal J, Barnwal P. Flaxseed: a potential source of food, feed and fiber. Crit Rev Food Sci Nutr 2011; 51: 210-222 [PMID: 21390942 DOI: 10.1080/10408390903537241]
75. Kaithwas G, Majumdar DK. Evaluation of antiulcer and antisecretory potential of Linum usitatissimum fixed oil and possible mechanism of action. Inflammopharmacology 2010; 18: 137-145 [PMID: 20405222 DOI: 10.1007/s10787-010-0037-5]
76. Tülüce Y, Ozkol H, Koyuncu I. Photoprotective effect of flax seed oil (Linum usitatissimum L.) against ultraviolet C-induced apoptosis and oxidative stress in rats. Toxicol Ind Health 2012; 28: 99-107 [PMID: 21665902 DOI: 10.1177/074823 3711407239]
77. Bommareddy A, Zhang X, Schrader D, Kaushik RS, Zeman D, Matthees DP, Dwivedi C. Effects of dietary flaxseed on intestinal tumorigenesis in Apc(Min) mouse. Nutr Cancer 2009; 61: 276-283 [PMID: 19235044 DOI: 10.1080/01635580802419764]
78. Fattorusso E, Lanzotti V, Taglialatela-Scafati O, Cicala C. The flavonoids of leek, Allium porrum. Phytochemistry 2001; 57: 565-569 [PMID: 11394858 DOI: 10.1016/ S0031-9422(01)00039-5]
79. Fattorusso E, Lanzotti V, Taglialatela-Scafati O, Di Rosa M, Ianaro A. Cytotoxic saponins from bulbs of Allium porrum L. J Agric Food Chem 2000; 48: 3455-3462 [PMID: 10956133]
80. Heinonen MI, Ollilainen V, Linkola EK, Varo PT, Koivistoinen PE. Carotenoids in Finnish foods, vegetables, fruits and berries. J Agric Food Chem 1989; 37: 655-659 [DOI: 10.1021/ jf00087a017]
81. Evans WC. Trease and Evans pharmacognosy. 15th Ed. WB Saunders, 2002
82. Manosroi A, Jantrawut P, Akazawa H, Akihisa T, Manosroi J. Biological activities of phenolic compounds isolated from galls of Terminalia chebula Retz. (Combretaceae). Nat Prod Res 2010; 24: 1915-1926 [PMID: 21108118]
83. Chang CL, Lin CS. Phytochemical Composition, Antioxidant Activity, and Neuroprotective Effect of Terminalia chebula Retzius Extracts. Evid Based Complement Alternat Med 2012; 2012: 125247 [PMID: 21754945 DOI: 10.1155/2012/125247]
84. Das ND, Jung KH, Park JH, Mondol MA, Shin HJ, Lee HS, Park KS, Choi MR, Kim KS, Kim MS, Lee SR, Chai YG. Terminalia chebula extract acts as a potential NF-κB inhibitor in human lymphoblastic T cells. Phytother Res 2011; 25: 927-934 [PMID: 21509843 DOI: 10.1002/ptr.3398]
85. Sharma P, Prakash T, Kotresha D, Ansari MA, Sahrm UR, Kumar B, Debnath J, Goli D. Antiulcerogenic activity of Terminalia chebula fruit in experimentally induced ulcer in rats. Pharm Biol 2011; 49: 262-268 [PMID: 21323478]
86. Nair V, Singh S, Gupta YK. Anti-arthritic and disease modifying activity of Terminalia chebula Retz. in experimental models. J Pharm Pharmacol 2010; 62: 1801-1806 [PMID: 21054408 DOI: 10.1111/j.2042-7158.2010.01193.x]
87. Kim HG, Cho JH, Jeong EY, Lim JH, Lee SH, Lee HS. Growth-inhibiting activity of active component isolated from Terminalia chebula fruits against intestinal bacteria. J Food Prot 2006; 69: 2205-2209 [PMID: 16995525]
88. Zhou L, Satoh K, Takahashi K, Watanabe S, Nakamura W, Maki J, Hatano H, Takekawa F, Shimada C, Sakagami H. Reevaluation of anti-inflammatory activity of mastic using activated macrophages. In Vivo 2009; 23: 583-589 [PMID: 19567394]
89. Kim HJ, Neophytou C. Natural anti-inflammatory compounds for the management and adjuvant therapy of inflammatory bowel disease and its drug delivery system. Arch Pharm Res 2009; 32: 997-1004 [PMID: 19641880 DOI: 10.1007/ s12272-009-1704-1]
90. Al-Said MS, Ageel AM, Parmar NS, Tariq M. Evaluation of mastic, a crude drug obtained from Pistacia lentiscus for gastric and duodenal anti-ulcer activity. J Ethnopharmacol 1986; 15: 271-278 [PMID: 3724207 DOI: 10.1016/0378-8741(86)90165-0]
91. Kaliora AC, Stathopoulou MG, Triantafillidis JK, Dedoussis GV, Andrikopoulos NK. Alterations in the function of circulating mononuclear cells derived from patients with Crohn' s disease treated with mastic. World J Gastroenterol 2007; 13: 6031-6036 [PMID: 18023095 DOI: 10.3748/wjg.13.6031]
92. Kaliora AC, Stathopoulou MG, Triantafillidis JK, Dedoussis GV, Andrikopoulos NK. Chios mastic treatment of patients with active Crohn's disease. World J Gastroenterol 2007; 13: 748-753 [PMID: 17278198]
93. Al-Habbal MJ, Al-Habbal Z, Huwez FU. A double-blind controlled clinical trial of mastic and placebo in the treatment of duodenal ulcer. Clin Exp Pharmacol Physiol 1984; 11: 541-544 [PMID: 6395994 DOI: 10.1111/j.1440-1681.1984.tb00864.x]